Somatic mutations and immunotherapy outcome with CTLA-4 blockade in melanoma

New England Journal of Medicine

Volumn 371, Issue 23, 2014, Pages 2230-2232

  Boussiotis, Vassiliki A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; ANTINEOPLASTIC AGENT; IPILIMUMAB; MONOCLONAL ANTIBODY; TICILIMUMAB;

ANTIGEN EXPRESSION; BINDING AFFINITY; CANCER IMMUNOTHERAPY; DEGRADATION KINETICS; DNA SEQUENCE; EDITORIAL; ENDOCYTOSIS; GENETIC VARIABILITY; HUMAN; IMMUNOLOGICAL SYNAPSE; MELANOMA; MEMORY T LYMPHOCYTE; MISSENSE MUTATION; MUTATIONAL ANALYSIS; OUTCOME ASSESSMENT; PHARMACOLOGICAL BLOCKING; SEQUENCE ANALYSIS; SOMATIC MUTATION; T LYMPHOCYTE ACTIVATION; UPREGULATION; ANTAGONISTS AND INHIBITORS; FEMALE; GENETICS; MALE; SKIN TUMOR;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CTLA-4 ANTIGEN; FEMALE; HUMANS; MALE; MELANOMA; SKIN NEOPLASMS;

EID: 84918831563     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1413061     Document Type: Editorial

References (12)

1. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr., Kinzler KW. Cancer genome landscapes. Science 2013;339:1546-58.
2. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
3. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16.
4. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-703.
5. Erratum, N Engl J Med 2011;364:588.
6. Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature 2013;500:415-21.
7. Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986;233:1318-21.
8. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
9. Erratum, N Engl J Med 2010;363:1290.
10. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54.
11. Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014;371:2189-99.
12. Egen JG, Allison JP. Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength. Immunity 2002;16:23-35.